In a nutshell This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the...
Read More
In a nutshell This study evaluated the risk of pneumonitis (inflammation of the lung tissue) associated with immune checkpoint inhibitors (ICIs) for the treatment of patients with advanced melanoma. The data showed that ICIs were associated with a higher risk of pneumonitis compared with conventional chemotherapy in patients with advanced melanoma. Some...
Read More
In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT). Some background Immunotherapy is a type of cancer treatment that makes use of the...
Read More
In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT). Some background Immunotherapy is a type of cancer treatment that makes use of the immune...
Read More
In a nutshell This study evaluated the use of high-dose glucocorticoids (GCs) and their impact on the survival outcomes during anti-PD-1 therapy for the treatment of patients with advanced melanoma. The data showed that early high-dose GC use was associated with poorer outcomes after the onset of immune-related side effects. Some background...
Read More
In a nutshell This study looked at the skin-related side effects of immune checkpoint inhibitors in the treatment of melanoma. It found that the most common side effects were mild-to-moderate itching, rash, and vitiligo (loss of skin pigment). Some background Immune checkpoint inhibitors (ICIs) are a type of immune therapy used to...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of combining pembrolizumab (PEM; Keytruda)) and ipilimumab (IPI; Yervoy) for the treatment of advanced-stage melanoma in patients that have progressed after previous PD-1/L1 therapy. The study concluded that this combination was well tolerated and improved the...
Read More
In a nutshell This study evaluated the safety and effectiveness of nivolumab (Opdivo) in patients with advanced melanoma in a real-world practice. The study found that the safety and effectiveness of nivolumab in these patients were similar to that reported in clinical trials. Some background Melanoma is a form of skin cancer. In more advanced...
Read More
In a nutshell This study was carried out to assess whether immune related side effects (IRSE) of anti-PD1 therapy affect the survival of patients with advanced melanoma. The authors of this study found that patients who had IRSE had better outcomes. Some background Advanced melanoma is a form of skin cancer that comes from a cell called a...
Read More
In a nutshell This study was carried out to determine whether combination therapy with a standard-dose pembrolizumab (Keytruda) plus reduced-dose ipilimumab (Yervoy) could be used as a treatment option in patients with advanced melanoma. The study found that this combination had good outcomes and manageable side effects in...
Read More
In a nutshell This study compared the frequency of allergic reactions to different doses of three biological therapies in patients with advanced melanoma. The authors found that different doses of the three drugs reduced the number of allergic reactions. Some background Biological therapy has significantly improved treatment results for patients...
Read More
In a nutshell This study examined if certain immunotherapy drugs increased the risk of developing side effects in the gut in patients with cancer also receiving chemotherapy. The results showed that immunotherapy drugs increased the risks of developing gut-related side effects compared to chemotherapy alone. Some background Immunotherapy drugs that...
Read More
